drugset / Trial / NCT04400539
The IMmunotherapy Pleural 5-ALA PDT
NaSingle-groupOpen-labelTreatment
Summary
Pilot study of the feasibility of an innovative multimodal treatment combining intrapleural photodynamic therapy with videothoracoscopy followed by adjuvant immunotherapy with anti-PD-1 Nivolumab antibodies in patients with malignant pleural mesothelioma
Timeline
- Start
- 2022-05-09
- Primary completion
- 2026-05-09
- Completion
- 2026-05-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 240 mg | Intravenous |